Treatment of Community-Acquired Pneumonia in Elderly Patients

Introduction to Treatment Approaches

The American Thoracic Society recommends using a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) as monotherapy for outpatient treatment of community-acquired pneumonia in elderly patients allergic to cephalexin and ciprofloxacin, or combining it with aztreonam 2 g IV every 8 hours for hospitalized patients requiring ICU admission 1, 2

For elderly outpatients without significant comorbidities, the American College of Chest Physicians suggests doxycycline 100 mg orally twice daily as a preferred alternative, with consideration of 200 mg as the first dose to achieve adequate serum levels more rapidly 1, 3
For elderly outpatients with comorbidities, the Infectious Diseases Society of America recommends levofloxacin 750 mg orally daily or moxifloxacin 400 mg orally daily as monotherapy, providing strong evidence-based coverage 1, 4

For hospitalized elderly patients not requiring ICU admission, the American Thoracic Society recommends respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) as the preferred regimen, with strong recommendation and high-quality evidence 1, 5
For ICU patients, the Society of Critical Care Medicine suggests levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily plus aztreonam 2 g IV every 8 hours, providing dual coverage against pneumococcal and gram-negative pathogens 2, 3, 5

If Pseudomonas aeruginosa risk factors are present, the American College of Chest Physicians recommends using levofloxacin 750 mg IV daily plus aztreonam 2 g IV every 8 hours plus an aminoglycoside (gentamicin or tobramycin 5-7 mg/kg IV daily) 5, 6
If MRSA is suspected, the Infectious Diseases Society of America suggests adding vancomycin 15 mg/kg IV every 8-12 hours or linezolid 600 mg IV every 12 hours to the base regimen 2, 3, 5

The American Thoracic Society recommends treating for a minimum of 5 days and until the patient is afebrile for 48-72 hours with no more than one sign of clinical instability, with a typical duration of 5-7 days for uncomplicated pneumonia 1, 2, 4
Extended duration (14-21 days) is required for confirmed Legionella pneumophila, Staphylococcus aureus, or gram-negative enteric bacilli 1, 2, 4

The American College of Emergency Physicians advises against delaying antibiotic administration, as delays beyond 8 hours increase 30-day mortality by 20-30% 2, 4
The Infectious Diseases Society of America recommends avoiding macrolide monotherapy in elderly patients with pneumonia requiring hospitalization, as it provides inadequate coverage for typical bacterial pathogens and resistance rates exceed 25% in many areas 1, 2, 4